Thus far, September has been a wild experience of ups and downs. Following the latest bout of volatility, shares have ticked greater once more. However as uncertainty concerning one other rescue program and the presidential election continues to linger, the place does the market go from right here? Weighing in for Oppenheimer, Chief Funding Strategist John Stoltzfus argues that any market dips seem “comparatively contained and orderly,” and current longer-term traders the possibility to seek out “infants that obtained thrown out with the bathwater.” He famous, “For nervous traders the latest downdraft has offered alternative to take some earnings with out FOMO (worry of lacking out).”As for the tech heavyweights that powered the market’s five-month cost ahead, the strategist believes “present expectations that expertise shares will stay below stress for a while appear exaggerated.” Stoltzfus provides that the “core of expertise shares didn’t seem terribly wealthy in value contemplating that developments in expertise and innovation have but to point out indicators of plateauing within the present cycle.”Taking Stoltzfus’ outlook into consideration, our focus turned to shares that Oppenheimer analysts are bullish on. The agency’s professionals see triple-digit upside potential in retailer for 3 tickers particularly. Working the names by way of TipRanks’ database, we wished to seek out out what makes every so compelling.MediWound Ltd. (MDWD)Creating cutting-edge merchandise, MediWound desires to handle unmet wants within the fields of extreme burn and power wound administration. With an essential authorities contract secured, Oppenheimer has excessive hopes for this identify.Again in January, MDWD introduced that the U.S. Biomedical Superior Analysis and Improvement Authority (BARDA) had entered right into a contract to obtain $16.5 million of NexoBrid, its drug designed to take away eschar in adults with deep partial and full-thickness thermal burns (a course of known as debridement), for an emergency stockpile. In line with administration, the primary supply is about for Q3 2020.On prime of this, the corporate filed the NexoBrid Biologics License Utility (BLA) with the FDA for eschar elimination in adults with deep partial-thickness and full-thickness thermal burns in June. MDWD’s U.S. business accomplice, Vericel, is getting ready for a right away launch upon approval.Representing Oppenheimer, 5-star analyst Kevin DeGeeter factors out that “Given the submitting concerned participation from three events—MDWD, U.S. business accomplice Vericel and funding companions at BARDA—and was accomplished in opposition to the backdrop of public sector work-from-home mandates, we view assembly said timelines as a cloth milestone and derisking occasion for MDWD shares… we consider NexoBrid is on observe for 1H21 launch.”Ought to the remedy finally be authorized, MDWD is entitled to a $7.5 million milestone fee from Vericel. “We consider the mixture of current money and the $7.5 million milestone fee from VCEL upon NexoBrid approval ought to fund operations no less than into 2H23,” DeGeeter added.DeGeeter additionally factors out that MDWD plans to open 25-30 websites in U.S. and Israel to assist the Section 2 examine of EscharEx, its product for power wounds. Though COVID-19 resulted in a delay, the analyst thinks “the present timeline of 1H21 is achievable.”To this finish, DeGeeter charges MDWD an Outperform together with a $7 value goal. Ought to his thesis play out, a possible twelve-month acquire of 117% might be within the playing cards. (To look at DeGeeter’s observe document, click on right here)All in all, different analysts echo DeGeeter’s sentiment. four Buys and no Holds or Sells add as much as a Sturdy Purchase consensus ranking. With a median value goal of $6.63, the upside potential is available in at 106%. (See MDWD inventory evaluation on TipRanks)UroGen Pharma (URGN)Primarily centered on uro-oncology, UroGen Pharma develops superior non-surgical remedies to enhance the lives of sufferers. Because the launch of one among its merchandise is progressing properly, Oppenheimer thinks that now could be the time to get on board.Writing for the agency, analyst Leland Gershell factors to UGN-101 as a key part of his bullish thesis. UGN-101, which has now been formally launched within the U.S. below the business identify Jelmyto, was designed as a therapy for low-grade higher tract urothelial carcinoma (LG UTUC). The analyst highlights that Jelmyto’s launch is already off to a stable begin, as eight sufferers had obtained 20 doses of the drug in June.“Jelmyto gross sales have been $371,000 in its first month of launch, however extra essential was administration’s commentary that over 100 urology apply websites are treatment-ready for the product, and that affected person demand has not been visibly impacted by COVID-19,” Gershell defined.Including to the excellent news, everlasting C- and J-codes, that are anticipated in October and January 2021, respectively, may bolster gross sales, in Gershell’s opinion. The label is also up to date to mirror accomplished OLYMPUS knowledge.It needs to be famous that affected person and doctor engagement may stay diminished by way of YE20, and restrictions round elective surgical procedures may persist, based on Gershell. That stated, he argues that “LG UTUC’s lack of surgical urgency may suggest therapy deferral for a number of months, whereas Jelmyto’s capacity to be administered in an outpatient setting may expedite therapy, favoring adoption.”If that wasn’t sufficient, UGN-102, its mitomycin gel that targets low-grade intermediate threat non-muscle invasive bladder most cancers (LG IR-NMIBC), is about to enter pivotal testing earlier than the top of 2020. Taking a look at beforehand launched knowledge, the remedy achieved a 65% full response (CR) charge at three months following onset of therapy. “To offset any potential COVID-19 affect on enrollment, URGN has elevated the variety of scientific trial websites outdoors of the U.S., in these nations the place virus-related scientific delays haven’t cropped up,”Gershell added.Summing all of it up, Gershell commented, “We consider shares commerce at a reduction to the worth of Jelmyto and UGN-102, and that income development will assist inventory upside over the following 12 months.”To this finish, Gershell stands with the bulls, reiterating an Outperform ranking. At $48, his value goal brings the upside potential to 123%. (To look at Gershell’s observe document, click on right here)What does the remainder of the Avenue need to say? three Purchase rankings and 1 Maintain have been issued within the final three months. In consequence, URGN receives a Sturdy Purchase consensus ranking. As well as, the $44 common value goal suggests 104% upside potential. (See URGN inventory evaluation on TipRanks)Ayala Prescription drugs Inc. (AYLA)Final however not least now we have Ayala Prescription drugs, which is concentrated on growing focused therapies for cancers wherein Notch activation is a recognized tumor driver. Primarily based on the progress throughout its growth pipeline, Oppenheimer sees massive features in retailer.Oppenheimer analyst Jay Olson thinks AYLA’s expertise makes it a stand-out. Its two candidates, AL101 and AL102, that are in-licensed from Bristol Myers, are gamma-secretase inhibitors that focus on aberrant activation of Notch signaling in most cancers cells.Notch signaling performs an essential function in regular cell growth, and perturbations could cause malignant transformation. “We consider Notch focused therapies maintain promise in addressing unmet scientific wants,” Olson commented.The analyst added, “The Notch mutational panorama is various, and the underlying science is evolving. AYLA is constructing a bioinformatics database round Notch to higher characterize and determine Notch-activating mutations. Moreover, AYLA is collaborating with companions growing diagnostic checks for Notch-activating mutations, each at DNA and RNA ranges. We consider these initiatives profit AYLA in the long run by figuring out responders and increasing the addressable affected person inhabitants.”Regardless of the challenges offered by COVID-19, essential catalysts stay on observe. The corporate is about to current new interim knowledge from the Section 2 ACCURACY open-label examine of AL101 in R/M ACC on the mini oral head and neck most cancers part of ESMO. Trying on the accessible knowledge, a latest interim evaluation in a single cohort confirmed 69% DCR.As for the second cohort, it’s evaluating a 6mg once-weekly dosing of AL101. “We view the efficacy and security knowledge from the 6mg dosing cohort as essential for the registration-enabling research, and we anticipate related interim knowledge readout in 1H21,” Olson stated.Including to the excellent news, AYLA is on observe to kick off affected person dosing within the Section 2 TENACITY examine of AL101 in R/M TNBC by YE20 after the IND was cleared by the FDA in April. In 2021, AYLA plans to provoke two extra Section 2 research together with AL102 for desmoid tumors and AL101 for r/r T-ALL.“Springworks Therapeutics lately introduced the completion of affected person enrollment of the Section three DeFi trial of nirogacestat in desmoid tumors with topline knowledge anticipated mid-2021, which ought to present read-across to AYLA’s AL102 program,” Olson famous.Given the entire above, Olson opined, “We’re inspired by AYLA’s benefits alongside a number of dimensions, together with its drug candidates, most cancers indication choice, and deal with figuring out Notch-activating mutations whereas growing diagnostics. AYLA’s Notch focused method ought to tackle unmet scientific wants for sufferers with uncommon however aggressive cancers.”It ought to come as no shock, then, that Olson stayed with the bulls. To this finish, he stored an Outperform ranking and $23 value goal on the inventory, implying 123% upside potential. (To look at Olson’s observe document, click on right here)Trying on the consensus breakdown, 2 Buys and 1 Maintain have been printed within the final three months. Due to this fact, AYLA will get a Reasonable Purchase consensus ranking. Primarily based on the $19.83 common value goal, shares may climb 92% greater within the subsequent 12 months. (See AYLA inventory evaluation on TipRanks)To seek out good concepts for shares buying and selling at enticing valuations, go to TipRanks’ Greatest Shares to Purchase, a newly launched device that unites all of TipRanks’ fairness insights.Disclaimer: The opinions expressed on this article are solely these of the featured analysts. The content material is meant for use for informational functions solely. It is vitally essential to do your personal evaluation earlier than making any funding.